Anticoagulant drugs: an update

References

• Hirsh J, Hoak J. Management of deep-vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 93, 2212–2245 (1996).
   PubMed Web of Science ®Google Scholar
• Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J. Med 326, 800–806 (1992).
   PubMed Web of Science ®Google Scholar
• Schulman S. Novel anticoagulant agents: introduction. J. Intern. Med 254,308–312 (2003).
   PubMed Web of Science ®Google Scholar
• Lee AY, Vlasuk GP Recombinant nematode anticoagulant protein C2 and other inhibitors targeting blood coagulation Factor Vila/tissue factor. J Intern. Med 254, 313–321 (2003).
   PubMed Web of Science ®Google Scholar
• Gustafson D. Oral direct thrombin inhibitors in clinical development. J. Intern. Med 254, 322–334 (2003).
   PubMed Web of Science ®Google Scholar
• Hirsh J. Heparin. N Engl J. Med 324, 1565–1574 (1991).
   PubMed Web of Science ®Google Scholar
• Hirsh J. Oral anticoagulant drugs. N Engl Med 324, 1865–1875 (1991).
   PubMed Web of Science ®Google Scholar
• Hirsh J, Dalen JE, Anderson DR et al Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 114, S445—S469 (1998).
   Web of Science ®Google Scholar
• •Comprehensive review on warfarin, used by physicians as the guideline for oral anticoagulation.
   Google Scholar
• Hirsh J, Raschke R, Warkentin TE et al Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 108, S258—S275 (1995).
   Web of Science ®Google Scholar
• •Comprehensive review on unfractionated heparin, used by physicians as the guideline for heparin therapy.
   Google Scholar
• Palareti G, Leali N. Bleeding complications of oral anticoagulant treatment: inception-cohort, prospective collaborative study (ISCOAT). Lancet 348, 423–428 (1996).
   PubMed Web of Science ®Google Scholar
• •Results of a long-term study on oral anticoagulants in a large number of patients.
   Google Scholar
• Palareti G, Hirsh J, Legnani C et al Oralanticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch. Intern. Med. 28, 470–478 (2000).
   Google Scholar
• Koopman MM, Prandoni P, Piovella F et al Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administrated at home. The Tasman Study Group. N Engl J. Med. 334, 682–687 (1996).
   PubMed Web of Science ®Google Scholar
• Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N EngL J. Med. 334, 677–681 (1996).
   Google Scholar
• Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86, 385–391 (1990).
   PubMed Web of Science ®Google Scholar
• Girardi G, Berman J, Redecha P et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112, 1644–1654 (2003).
   PubMed Web of Science ®Google Scholar
• Green D, Hull RD, Brant R, Pineo GE Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339, 1476 (1992).
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Buller HR et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339, 441–445 (1992).
   PubMed Web of Science ®Google Scholar
• Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am. J. Med. 100, 269–277 (1996).
   PubMed Web of Science ®Google Scholar
• Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep-venous thrombosis: a meta-analysis of randomized, controlled trials. Ann. Intern. Med. 130,800–809 (1999).
   PubMed Web of Science ®Google Scholar
• Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler. Thromb. Vasc. Biol. 23,2110-2115 (2003).
   Google Scholar
• McLean J. The thromboplastic action of cephalin. Am. J. PhysioL 41,250–257 (1916).
   Google Scholar
• Howell WH, Holt E. Two new factors in blood coagulation — heparin and proantithrombin. Am. J. PhysioL 47, 328–341 (1918).
   Google Scholar
• Link KR The anticoagulant from spoiled sweet-clover hay. Harvey Lectures 39, 152–216 (1943).
   Google Scholar
• Davie EW. A brief historical review of the waterfall/cascade of blood coagulation. J. Biol. Chem. 278,50819–50832 (2003).
   PubMed Web of Science ®Google Scholar
• •Excellent and comprehensive up-to-date review on the evolving concept of the process of coagulation.
   Google Scholar
• Mann KG. Thrombin formation. Chest 124\(Suppl. 3), S4—S10 (2003).
   Google Scholar
• Morrissey JH. Tissue factor: in at the start and the finish? J. Thromb. Haemost. 1, 878–880 (2003).
   Web of Science ®Google Scholar
• •Excellent and comprehensive up-to-date review on tissue factor.
   Google Scholar
• Butenas S, Mann KG. Blood coagulation. Biochemistry 67,3–12 (2002).
   PubMed Web of Science ®Google Scholar
• •Excellent and comprehensive up-to-date review on the process of coagulation.
   Google Scholar
• Broze GJ. Tissue factor pathway inhibitor. Thromb. Haemost 74,90–93 (1995).
   PubMed Web of Science ®Google Scholar
• •Excellent and comprehensive review on tissue factor pathway inhibitor
   Google Scholar
• Sajadi S, Ezekowitz MD, Dhond A, Netrebko R Tissue factor pathway inhibitors as a novel approach to antithrombotic therapy. Drug News Perspeci. 16,363–369 (2003).
   PubMedGoogle Scholar
• Lee AY, Vlasuk GP. Recombinant nematode anticoagulant protein C2 and other inhibitors targeting blood coagulation Factor Vila/tissue factor. J. Intern. Med 254,312–321(2003).
   Web of Science ®Google Scholar
• Rusconi CP, Scardino E, Layzer J et al. RNA aptamers as reversible antagonists of coagulation Factor IXa. Nature 419,90–94 (2002).
   PubMed Web of Science ®Google Scholar
• Esmon CT, Ding W, Yasuhiro K et al. The protein C pathway: new insights. Thromb. Haemost 78,70–74 (1997).
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent JL, Laterre PF et al Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N EngL J. Med 344,699–709 (2001).
   PubMed Web of Science ®Google Scholar
• Griffin JH, Zlokovic B, Fernandez JA. Activated protein C: potential therapy for severe sepsis, thrombosis and stroke. Semin. HematoL 39,197–205 (2002).
   PubMed Web of Science ®Google Scholar
• Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb. Res. 106,275–284 (2002).
   Web of Science ®Google Scholar
• Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 105, 1004–1011 (2002).
   PubMed Web of Science ®Google Scholar
• Mustard JF. The relationship between the structure of a thrombus or a hemostatic plug and the mechanisms involved in its formation. Thromb. Diath. Haemorrha. 28(Suppl.), 57–64 (1968).
   Google Scholar
• Rosenberg RD, Aird WC. Vascular bed specific hemostasis and hypercoagulable state. N EngL J Med. 340,1555–1564 (1999).
   PubMed Web of Science ®Google Scholar
• •Classic paper describing how hemostasis should be viewed from the vascular viewpoint.
   Google Scholar
• Hirsh J, Dalen J, Anderson DR et al Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 119, S8—S21 (2001).
   Web of Science ®Google Scholar
• •Excellent up-to-date review on oral anticoagulants.
   Google Scholar
• Hirsh J, Warkentin TE, Shaughnessy SG et al Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 119, S64—S94 (2001).
   Web of Science ®Google Scholar
• •Excellent up-to-date review on heparin.
   Google Scholar
• Hirsh J, Bates SM. The emerging role of low-molecular-weight heparin in cardiovascular medicine. Prog. Cardiovasc. Dis. 42,235–246 (2000).
   PubMed Web of Science ®Google Scholar
• Weitz JI. Low-molecular-weight heparins. N EngL J. Med. 337,688–698 (1997).
   PubMed Web of Science ®Google Scholar
• Choay J, Petitou M, Lormeau JC et al Structure activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-Factor Xa activity. Biochem. Biophys. Res. Comm. 116,492–499 (1983).
   PubMed Web of Science ®Google Scholar
• Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb. Res. 109,1–11 (2003).
   PubMed Web of Science ®Google Scholar
• Olson ST, Björk I, Sheffer R et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J. Bid. Chem. 267,12528–12538 (1992).
   PubMed Web of Science ®Google Scholar
• Walenga JM, Jeske WP, Samama MM et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin. Investig. Drugs 11(3), 397–407 (2002).
   Google Scholar
• •Detailed summary of the pharmacology of pentasacchide.
   Google Scholar
• Walenga JM, Petitou M, Lormeau JC et al Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb. Res. 46, 187–198 (1987).
   PubMed Web of Science ®Google Scholar
• Lormeau JC, Herault JP, Herbert JM. Antithrombin-mediated inhibition of Factor Vila-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb. Haemost 76,5–8 (1996).
   PubMed Web of Science ®Google Scholar
• Hemker HC, Choay J, Beguin S. Free Factor Xa is on the main pathway of thrombin generation in clotting plasma. Biochem. Biophys. Acta 992,409–411 (1989).
   PubMedGoogle Scholar
• Herault JP, Bernat A, Pflieger AM, Lormeau JC, Herbert JM. Comparative effects of two direct and indirect Factor Xa inhibitors on free and clot-bound prothrombinase. J. PharmacoL Exp. The,: 283,16–22 (1997).
   PubMed Web of Science ®Google Scholar
• Donat F, Duret JP, Santoni A et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin. Pharmacoki net. 41(Suppl. 2), 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359,1715–1720 (2002).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359,1721–1726 (2002).
   PubMed Web of Science ®Google Scholar
• Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N EngL J. Med. 345,1305–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N EngL J. Med. 345,1298–1304 (2001).
   PubMed Web of Science ®Google Scholar
• Elalamy I, Lecrubier C, Potevin F et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb. Haemost. 74,1384–1385 (1995).
   PubMed Web of Science ®Google Scholar
• Van Amsterdam R, Vogel G, Visser A et al. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vitro residence time. Atter. Thromb. Vasc. BioL 15, 495–503 (1995).
   PubMed Web of Science ®Google Scholar
• Herbert JM, Herault JP, Bernat A et al. Biochemical and pharmacological properties of SANORG 32701. Comparison with the 'synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin. Circ. Res. 79, 590–600 (1996).
   PubMed Web of Science ®Google Scholar
• PERSIST Investigators. A novel long-acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep-vein thrombosis. A Phase II evaluation. Blood 100, 301 (2002).
   Web of Science ®Google Scholar
• Prasa D, Svendsen L, Sturzebecher J. Inhibition of thrombin generation in plasma by inhibitors of Factor Xa. Thromb. Haemost. 78,1215–1220 (1997).
   PubMed Web of Science ®Google Scholar
• Kaiser B, Jeske W, Walenga JM, Fareed J. Inactivation of Factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Blood Coag. Fibrinolysis 10, 495–501 (1999).
   PubMed Web of Science ®Google Scholar
• Tobu M, Iqbal 0, Ma Q et al. Global anticoagulant effects of a synthetic anti-Factor Xa inhibitor (DX-9065a): implications for interventional use. Clin. AppL Thromb. Hemost. 9,1–17 (2003).
   PubMed Web of Science ®Google Scholar
• Haycraft JB. The action of a secretion obtained from the medicinal leech on the coagulation of the blood. Proc. R Soc. Land. 36,478–487 (1884).
   Google Scholar
• Stringer KA, Lindenfeld J. Hirudins: antithrombin anticoagulants. Ann. Pharmacother. 26,1535–1540 (1992).
   PubMed Web of Science ®Google Scholar
• Stone SR, Hofsteenge J. Kinetics of inhibition of thrombin by hirudin. Biochemistry 25,4622–4628 (1986).
   PubMed Web of Science ®Google Scholar
• Rydel TJ, Ravichandran KG, Tulinsky A et al The structure of a complex of recombinant hirudin and human a-thrombin. Science 249,277–280 (1990).
   PubMed Web of Science ®Google Scholar
• Eichler P, Friesen HJ, Lubenow N et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT and clinical relevance. Blood 96, 2373–2378 (2000).
   PubMed Web of Science ®Google Scholar
• Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterisation of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29,7095–7101 (1990).
   PubMed Web of Science ®Google Scholar
• Scatena R Bivalirudin : a new generation antithrombotic drug. Expert Opin. Investig Drugs 9(9), 1119–1127 (2000).
   PubMedGoogle Scholar
• Chew DP, Bhatt DL, Kimball W et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am. J. CardioL 92,919–923, (2003).
   PubMed Web of Science ®Google Scholar
• Kong DF, Topol EJ, Bittl JA et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 10,2049–2053 (1999).
   Google Scholar
• Eichler P, Lubenow N, Strobel U, Greinacher A. Antibody against lepirudin are polyspecific and recognizes epitopes on bivalirudin. Blood 103,13–16 (2003).
   PubMed Web of Science ®Google Scholar
• Okamoto S, Hijikata A, Kikumoto R et al Potent inhibition of thrombin by the newly synthesized arginine derivative number 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem. Biophys. Res. Commun. 101,440–446 (1981).
   PubMed Web of Science ®Google Scholar
• Hijikata-Okunomiya A, Okamoto S, Wanaka K. Effect of a synthetic thrombin-inhibitor MD805 on the reaction between thrombin and plasma antithrombin III. Thromb. Res. 59,967–977 (1990).
   PubMed Web of Science ®Google Scholar
• Hijikata-Okunomiya A, Kataoka N. Argatroban inhibits staphylothrombin. J. Thromb. Haemost. 1,2060–2061 (2003).
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Alford KL, Becker JC et al. Novastan (brand of argatroban): a small molecule, direct thrombin inhibitor. Semin. Thromb. Hemost. 23,503–516 (1997).
   PubMed Web of Science ®Google Scholar
• Fareed J, Lewis BE, Callas DD et al Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Clin. AppL Thromb. Hemost. 5, S45—S55 (1999).
   Web of Science ®Google Scholar
• •Excellent detailed description of the pharmacology of the direct antithrombin agents.
   Google Scholar
• Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103, 1838–1843 (2001).
   PubMed Web of Science ®Google Scholar
• Kondo LM, Wittkowsky AK, Wiggins BS. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Ann. Pharmacother. 35, 440–451 (2001).
   PubMed Web of Science ®Google Scholar
• Gustafsson D, Nystrom JE, Carlsson S et al The direct thrombin inhibitor melagatran and its oral prodrug H376/95, intestinal absorption properties, biochemical and pharmacodynamic effect. Thromb. Res. 101, 171–118 (2001).
   PubMed Web of Science ®Google Scholar
• Nylander S, Matsson C. Thrombin induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood Coag FibrinoL 14,1–9 (2003).
   PubMed Web of Science ®Google Scholar
• Sarich TC, Woltz M, Eriksson UG et al Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J. Am. ColL CardioL 41,557–564 (2003).
   PubMed Web of Science ®Google Scholar
• Lebrazi J, Elalamy I, Samama MM. In vitro effect of melagatran and lepirudin on clot bound thrombin. Thromb. Res. 110, 249–252 (2003).
   Google Scholar
• Gustafsson D, Antonsson T, Bylund R et al Effects of melagatran, a new low-molecular-weight thrombin inhibitor on thrombin and fibrinolytic enzymes. Thromb. Haemost. 79, 110–118 (1998).
   PubMed Web of Science ®Google Scholar
• Eriksson UG, Bredberg U, Gislen K et al Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur. J. Clin. PharmacoL 59(1), 35–43 (2003).
   PubMed Web of Science ®Google Scholar
• Eriksson H, Eriksson U, Frison L et al Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb. Haemost. 81,358–363 (1999).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Arfwidsson A-C, Frison L et al A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb. Haemost. 87,231–237 (2002).
   PubMed Web of Science ®Google Scholar
• Kelley RF, Refino CJ, O'Connell MP et al. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 89,3219–3227 (1997).
   PubMed Web of Science ®Google Scholar
• Taylor FB Jr. Role of tissue factor and Factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. Haemostasis 26,83–91 (1996).
   PubMedGoogle Scholar
• •Analyzes the pathogenesis of sepsis and the role of coagulation.
   Google Scholar
• Rivera TM, Leone-Bay A, Paton DR et al Oral delivery of heparin in combination with sodium N-(8-(2-dyfroxybenzoyl) amino) caproate: pharmacological considerations. Pharm. Res. 14, 1830–1834 (1997).
   PubMed Web of Science ®Google Scholar
• Brayden D, Creed E, O'Connell A et al Heparin absorption across the intestine: effect of sodium N-(8-(2-dyfroxybenzoyl) amino) caproate in rat in situ intestinal instillations and Caco-2 monolayers. Pharm. Res. 14, 1772–1779 (1997).
   PubMed Web of Science ®Google Scholar
• Benedict CR, Ryan J, Wolitzky B et al Active site-blocked Factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin. Invest. 88, 1760–1765 (1991).
   PubMed Web of Science ®Google Scholar
• Gomi K, Zushi M, Honda G et al. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 75, 1396–1399 (1990).
   PubMed Web of Science ®Google Scholar
• Feuerstein GZ, Toomey JR, Valocik R et al. An inhibitory anti-Factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis. Thromb. Haemosi. 82, 1443–1545 (1999).
   PubMed Web of Science ®Google Scholar
• Brady SF, Stauffer KJ, Lumma WC et al. Discovery and development of the novel potent orally-active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)proly1 trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analog synthesis on solid support. J. Med. Chem. 41, 401–406 (1998).
   PubMed Web of Science ®Google Scholar